Currently, many DNA vaccines against infectious diseases are in clinical trials; however, their efficacy needs to be improved. The potency of DNA immunogen can be optimized by targeting technologies. In the current study, to increase the efficacy of NS1 encoded by plasmid, proteasome targeting was applied. NS1 variants with or without translocation sequence and with ornithine decarboxylase as a signal of proteasomal degradation were tested for expression, localization, protein turnover, proteasomal degradation and protection properties. Deletion of translocation signal abrogated presentation of NS1 on the cell surface and increased proteasomal processing of NS1. Fusion with ornithine decarboxylase led to an increase of protein turnover and the proteasome degradation rate of NS1. Immunization with NS1 variants with increased proteasome processing protected mice from viral challenge only partially; however, the survival time of infected mice was prolonged in these groups. These data can give a presupposition for formulation of specific immune therapy for infected individuals.
Nowadays, Flavivirus infections are becoming more widespread all over the world. DNA vaccines are one of the candidates being intensively developed against viruses of this genus [1] . The composition of viral antigens to be included in vaccines should be carefully determined. Among flavivirus proteins, nonstructural protein 1 (NS1) is a very attractive target because it is very conservative and elicits an immune response during infection [2, 3] . DNA immunization with NS1 was able to protect mice from Japanese encephalitis virus, dengue virus and tick-borne encephalitis virus (TBEV) [4] [5] [6] [7] [8] .
The NS1 protein of flaviviruses is distributed in different cellular compartments in different forms. In the cytoplasm of the cell, NS1 protein is detected as a monomer. In the endoplasmic reticulum (ER) and cellular membrane, NS1 is detected as a homodimer [9, 10] . Some protein molecules are secreted and form a hexamer outside the cell [11] [12] [13] .
Used as a vaccine immunogen, NS1 is able to provide complement-dependent and -independent antibodymediated protection and has also been identified as a target of cell-mediated immunity [3] . Correlates of protection are still under discussion and seem to be specific to individual flaviviruses. Protection from TBEV by NS1 was associated with eliciting non-neutralizing antibodies and the Th1 response [14] .
However, there are several concerns regarding the use of NS1 as an immunogen. One is the fact that, in some cases, the antibodies to NS1 cross-react with host components [15, 16] . These autoantibodies can be harmful for the host and worsen disease progression. The second fact is that secreted NS1 interacts with complement components C4 and C1s, which causes inhibition of the classical and lectin pathways of complement activation [17] .
In this work, we decided to diminish these side effects by decreasing the secretion of NS1 and further enhancing the T cell immunity of NS1 as a DNA vaccine immunogen by targeting technology. A variety of strategies to improve the immunogenicity of genetic DNA vaccines have been developed [18, 19] , one of which is targeting technology. Protein targeting for different proteolysis routes modifies the natural route of protein processing and presentation [20] and, as a consequence, leads to modification of its immunogenic properties. Antigens presented by MHC class I activate CD8 + T cells after being processed by proteasome [21] , whereas lysosome-processed antigens are presented in MHC class II and recognized by CD4 + T cells. Targeting can be achieved by addition of specialized signal sequences [22] . For instance, cellular immune response may be improved when antigens are targeted to the MHC I presentation pathway by different mechanisms. This technology was successfully used for different antiviral DNA vaccines. Enhancement of proteasomal degradation of HIV-1 nef protein [23] , M1 and NS1 proteins of influenza virus [24] and HIV-1 reverse transcriptase [25] [26] [27] was used to strengthen the cellular immune response to DNA vaccines. Also, retargeting of antigen to ER was used for the same purpose [28] .
Here we tested the protectivity and immunogenicity of NS1 variants with signals for secretion and degradation by proteasome. We aimed to decrease the secretion and surface presentation of NS1 by deleting the translocation signal. For further increase of Th1 immunity, we targeted NS1 to proteasome degradation by adding the proteasome degradation signal. Localization, protein turnover and rate of proteasomal degradation in the cell were characterized for NS1 variants. Then, mice were immunized with plasmids encoding these variants, and protection against lethal challenge was assessed. In immunization experiments, the NS1 variants showed different protective efficacy and survival time of infected animals.
The processing pathway of antigenic protein and its presentation in the MHC molecules directs the type of immune response it elicits. The proteasomal system of degradation generates peptides for presentation in MHC class I that are recognized by Th1 T cells. In the current study, we manipulated the localization and degradation of NS1 of TBEV in cells with the final aim of increasing MHC class I presentation to enhance the Th1 immune response. For this, several plasmids encoding NS1 variants were created. NS1 of flaviviruses is known to contain 25 C-terminal amino acid residues of envelope protein E on its N-terminus that are responsible for NS1 transport to ER and its secretion [9, 10] . This region is a transmembrane segment, TM2, for protein transport across the membrane [29] . We surmised that deletion of this leader sequence (Ld) of NS1 will abrogate protein transport out of the cell and will increase the accessibility for generation of epitopes for MHC class I. Thus, the first plasmid variant encoded NS1 protein with the leader signal sequence on its N-end that is typical for the N-terminus of NS1 of TBEV (pLdNS1). Plasmid carrying the expression cassette encoding NS1 protein with leader sequence corresponding to aa 753-1128 of TBEV polyprotein of Neudorfl strain (UniProtKB/Swiss-Prot: P14336.4) has been described previously [30] . The second variant of the plasmid encoding NS1 without leader sequence corresponding to aa 778-1128 of TBEV polyprotein (pNS1) was generated by PCR and recloned into the same vector.
For further increase of the affinity of NS1 protein to proteasome, we created chimeric NS1 with a fast proteasome degrading protein. Ornithine decarboxylase (ODC) was chosen as the short-lived protein with a half-life of 30 min [31] . ODC degradation is directed by two short signals on its C-terminus, which form the minimal proteasome targeting signal, and also by a regulatory element at the N-terminus responsible for antizyme-mediated proteolysis [32] . Fusion of 53 C-terminal amino acids of ODC (ODCsig) led to destabilization of proteins [26, 33, 34] . The DNA fragment encoding the last 53 aa of ODC was generated by PCR [22, 25] and was cloned into LdNS1-and NS1-containing plasmids to generate plasmids pLdNS1-ODCsig and pNS1-ODCsig.
All generated plasmids were tested for NS1 expression in cell culture. HEK 293T cells were transfected with the plasmids encoding all NS1 variants, and 48 h later, accumulation of NS1 variants was analysed by Western blotting with monoclonal anti-NS1 1 : 10 000 (4C4 clone, Biosan). Proteins with expected molecular masses were detected in lysates of transfected cells (Fig. 1a) . The monomeric form of NS1 with expected molecular mass (46-47 kDa) [8] was detected in lysates of cells transfected with pLdNS1. Faster-migrating protein (43-44 kDa) was observed in pNS1-transfected cells. Chimeric LdNS1 and NS1 with ODC signal had 5-7 kDa higher molecular masses. Analysis of culture fluids with anti-NS1 antibodies revealed the presence of NS1 protein only for cells transfected with pLdNS1 (Fig. 1b) . This data indicated that deletion of leader sequence and fusion with ODC signal decreases NS1 secretion to undetectable levels.
Apart from secretion, the NS1 is exposed at cell surface and even in this form is able to elicit antibodies. So, next we tested the localization of NS1 variants on the cell surface. HeLa cells were transfected and 2 days later fixed with paraformaldehyde and stained with monoclonal anti-NS1 (Fig. 1c) . The strongest signal was observed for NS1 variant with a secretion signal LdNS1. A very faint signal was observed for LdNS1-ODCsig. Cells transfected with plasmids encoding NS1 variants without the leader sequence did not differ from untransfected cells. Thus, two out of four variants are exposed on the cell surface.
Protein localization alterations may lead to changes of protein turnover. The degradation rates were estimated for NS1 variants. For this, HEK 293T cells were transfected and on the second day after transfection an inhibitor of protein translation, cycloheximide, was added to the cell culture medium. Then cells were lysed at several time points, and the amount of retained protein was analysed by Western blotting (Fig. 2a) . Images were quantified using ImageJ software. The amount of LdNS1 and NS1 did not significantly change after 6 h blockage of translation, while ODCsig chimera content dropped more than twofold. This indicates that fusion of LdNS1 and NS1 with ODCsig led to increased protein turnover.
For estimation of proteasome processing involved in the turnover of the NS1 variants, proteasome inhibitors were applied. HEK 293T cells transfected with plasmid variants were treated with 5 µM MG132 and 0.1 µM epoxomicin for 18 h. Then the amount of NS1 was analysed by Western blotting, and images were quantified using ImageJ software (Fig. 2b) . Treatment of pLdNS1-transfected cells with proteasome inhibitors did not significantly affect the protein content. For NS1, a twofold increased accumulation in the cell after treatment with proteasome inhibitors was observed. MG132 treatment and epoxomicin dramatically increased the amount of ODCsig chimeric proteins by four- to eightfold. Thus, we achieved acceleration of NS1 proteasome processing by fusion with ODCsig.
Following the characterization of localization and degradation of NS1 variants, their protective properties were assessed in mice. BALB/c mice (males) were injected intramuscularly (im) with two doses of 50 µg plasmid in PBS. Two weeks after immunization, mice received intraperitoneally (ip) 25 LD 50 of TBEV (strain Absettarov) and were monitored for 21 days. Partial protection was observed in all groups (Fig. 3a) . Protection of mice immunized with pLdNS1 and pNS1 was statistically significant. Interestingly, in all groups of mice that received NS1 variants with increased proteasome degradation, prolongation of survival time was detected (Fig. 3b) .
Furthermore, we have tested the immunogenicity of these variants. BALB/c mice were immunized the same way, and 3 weeks later, antibody production was tested by estimation of Th1/Th2 immune response shift. IgG antibodies were detected only in pLdNS1 (1 : 4500) and pLdNS1-ODCsig (1 : 1500) DNA-immunized mice (Fig. 3c) . In pNS1 and pNS1-ODCsig groups, no antibodies were detected. The ability to induce antibodies reflected the properties of NS1 variants to be secreted and exposed on a cell surface as for LdNS1 or just to be presented at the cell membrane as for pLdNS1-ODCsig.
To illustrate Th1 or Th2 shift of immune response, the IgG1 and IgG2a antibodies were measured (Fig. 3c) . IgG1 titres were higher in the pLdNS1-immunized group (1 : 1200) than in the pLdNS1-ODCsig group (1 : 600). However, pLdNS1-ODCsig elicited higher IgG2a titres (1 : 350) as compared to pLdNS1 (1 : 100). Fusion with ODCsig led to increase of IgG2a antibodies, indicating a shift to Th1 immunity. For some flaviviruses, the importance of IgG2a antibodies in providing protection was observed. IgG2a isotype antiNS1 monoclonal antibodies were able to protect mice challenged with yellow fever virus [35] . Clearance of West-Nile-virus-infected cells can be processed by recognition of NS1-membane-bound NS1 by anti-NS1 IgG2a antibodies [36] . However, in the current study, DNA immunization with plasmid able to elicit higher IgG2a antibodies (pLdNS1-ODCsig) did not lead to increase of protection against TBEV as compared to the lower-eliciting NS1 variant (pLdNS1).
pNS1 and pNS1-ODCsig were unable to elicit significant levels of antibodies; however, partial protection was observed in these groups, indicating that cellular immune response is also involved in establishing protection by immunization with NS1 gene. The role of T-cell-mediated immunity in the course of flaviviral infections is controversial and intensively discussed [37] [38] [39] . In the case of TBEV, investigation of the T cell immune response is also needed. However, this was difficult for TBEV NS1 since none of the T cell epitope was localized [40] . A better understanding of T cell immunity is needed for the development of safe and efficacious vaccines.
This current work was dedicated to revealing the role of proteasomal degradation in establishing protection against TBEV infection by NS1. For this, we created and characterized the DNA constructs based on secreted NS1 and its short variant without secretion signal. We found out that deletion of the NS1 protein secretion signal decreased its expression but did not significantly increase degradation by proteasome, and protective activity was completely lost. Fusion with proteasome targeting signal with NS1 led to significant acceleration of protein proteasome degradation. Proteasome targeting of NS1 did not increase the protective activity of NS1. However, all NS1 variants with increased proteasomal processing were able to prolong the survival time of infected mice. This fact could form the basis for development of a specific therapeutic treatment for TBEV infection, such as early or emergent vaccination.
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